RxDoctor Payments Data

Thasarat Vajaranant, MD

Ophthalmology · Chicago, ILNPI 1700808763

Payments from drug & device makers

$9,092in general payments, 2019–2025

Across 18 payments — averaging $505.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Bausch & Lomb Americas Inc.$1K
  • NEW World Medical,inc.$297
  • Glaukos Corporation$203
  • Alcon$50
  • Aerie Pharmaceuticals, Inc.$24

What the payments were for

  • Speaking & faculty fees$1,00057%
  • Food & beverage$76843%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,092 in reported general payments places this provider in the 80th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$128,255
Medicare patients
352
Services billed
1,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate51$19,262
Methazolamide39$16,512
VyzultaLatanoprostene Bunod34$12,159
LumiganBimatoprost30$12,062
RocklatanNetarsudil Mesylat/Latanoprost21$10,194
SimbrinzaBrinzolamide/Brimonidine Tart32$7,545
CombiganBrimonidine Tartrate/Timolol23$6,024
Brimonidine Tartrate363$4,980
Latanoprost596$4,703
Brinzolamide30$4,581
Alphagan PBrimonidine Tartrate11$4,199
Dorzolamide-TimololDorzolamide/Timolol/Pf17$4,014
Travoprost41$3,953
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat293$3,787
Dorzolamide Hcl220$3,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$24$29,45672 claims
AbbVieLumigan, Combigan, Alphagan P$7,519$22,28564 claims
Bausch & Lomb Americas Inc.Vyzulta$1,000$12,15934 claims
AlconSimbrinza$50$7,54532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →